Expert Point of View: Peter Ravdin, MD

Get Permission

Peter Ravdin, MD

The NATAN study showed that zoledronic acid doesn’t work in that average woman in this trial [one with early breast cancer, residual tumor remaining after neoadjuvant therapy]. There is, however, a trend to modest benefit in women older than 55, which is consistent with statistically significant benefit seen in a meta-analysis for bisphosphonates in adjuvant therapy trials, as was shown by the meta-analysis presented here,” stated Peter Ravdin, MD, of San Antonio, Texas.

Dr. Ravdin believes that the National Comprehensive Cancer Network will consider the findings of the Oxford ­meta-analysis and possibly include bisphosphonates as adjuvant therapy for postmenopausal women. ■

Disclosure: Dr. Ravdin reported no potential conflicts of interest.

Related Articles

Zoledronic Acid Fails to Benefit Women With Chemoresistant Breast Cancer

Zoledronic acid does not improve outcomes in patients with early breast cancer who do not have a full response to neoadjuvant anthracycline/taxane–based chemotherapy, according to results of the Neo-Adjuvant Trial Add-On (NATAN) study presented at the 2013 San Antonio Breast Cancer Symposium.1 A...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.